Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pd-0166285. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 known ✓ | P11362 | 9/20 | 1.00 |
| ▸ | SRC known ✓ | P12931 | 6/20 | 1.00 |
| ▸ | PDGFRB known ✓ | P09619 | 3/20 | 1.00 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 8/20 | 1.00 |
| ▸ | NOD2 | Q9HC29 | 8/20 | 1.00 |
| ▸ | ACVR1 | Q04771 | 7/20 | 1.00 |
| ▸ | WEE1 | P30291 | 4/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 3/20 | 1.00 |
| ▸ | FGFR2 | P21802 | 2/20 | 1.00 |
| ▸ | FGFR4 | P22455 | 2/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 2/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | PAK4 | O96013 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pd-0166285 SCHEMBL30250248 | 1.00 | FGFR1 (1.00) | FGFR1RIPK2NOD2ACVR1SRC | |
| Pd-0166285 SCHEMBL15106017 | 0.99 | FGFR1 (0.98) | FGFR1RIPK2NOD2ACVR1SRC | |
| Pd-0166285 SCHEMBL30276696 | 0.99 | FGFR1 (0.98) | FGFR1RIPK2NOD2ACVR1SRC | |
| Pd-0166285 SCHEMBL15923205 | 0.98 | FGFR1 (0.97) | FGFR1RIPK2NOD2ACVR1SRC | |
| Pd-0166285 SCHEMBL29658286 | 0.98 | FGFR1 (0.97) | FGFR1RIPK2NOD2ACVR1SRC | |
| SCHEMBL10108147 | 0.95 | FGFR1 (0.91) | FGFR1RIPK2NOD2ACVR1SRC | |
| SCHEMBL10108496 | 0.94 | FGFR1 (0.89) | FGFR1RIPK2NOD2ACVR1SRC | |
| SCHEMBL20563458 | 0.92 | RIPK2 (1.00) | FGFR1RIPK2NOD2ACVR1SRC | |
| SCHEMBL29498246 | 0.92 | RIPK2 (1.00) | FGFR1RIPK2NOD2ACVR1SRC | |
| SCHEMBL10102543 | 0.90 | FGFR1 (0.86) | FGFR1RIPK2NOD2ACVR1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 521 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106952-A1 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | CDG CARE (US) | 2026-05-21 | — | — | WO | claimed |
| US-20250387643-A1 | METHODS AND APPARATUS FOR APPLYING TUMOR TREATING FIELDS COMBINED WITH PERSONALIZED ULTRA-FRACTIONATED STEREOTACTIC ADAPTIVE RADIOTHERAPY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-12-25 | — | — | US | claimed |
| US-20250360129-A1 | COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS | UNIV YALE (US) | 2025-11-27 | — | — | US | claimed |
| EP-3250192-B1 | COMPOSITIONS AND METHODS OF USING TYROSINE KINASE INHIBITORS | UNIV YALE (US) | 2025-10-08 | — | — | EP | claimed |
| US-20250302977-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING HUMANIZED ANTIBODIES TARGETING UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR ASSOCIATED PROTEIN (UPARAP) | RIGSHOSPITALET (DK) | 2025-10-02 | — | — | US | claimed |
| WO-2025202361-A1 | ANTI-GPC1 ANTIBODIES AND USES THEREOF | ADCENDO APS (DK) | 2025-10-02 | — | — | WO | claimed |
| US-12420113-B2 | Methods and apparatus for applying tumor treating fields combined with personalized ultra-fractionated stereotactic adaptive radiotherapy | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-09-23 | — | — | US | claimed |
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2025111339-A1 | TREATMENT OF CANCER WITH A PARG INHIBITOR | 858 THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2021202780-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2021-10-07 | — | — | WO | claimed |
| US-20080220497-A1 | Modulation of protein functionalities | DECIPHERA PHARMACEUTICALS LLC | 2008-09-11 | — | — | US | claimed |
| EP-1907411-A2 | MODULATION OF PROTEIN FUNCTIONALITIES | Deciphera Pharmaceuticals, LLC. (US) | 2008-04-09 | — | — | EP | claimed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | claimed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | claimed |
| WO-2007008917-A2 | MODULATION OF PROTEIN FUNCTIONALITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-01-18 | — | — | WO | claimed |
| EP-0823908-B1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2006-11-02 | — | — | EP | claimed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | claimed |
| EP-0823908-A1 | PYRIDO 2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1998-02-18 | — | — | EP | claimed |
| WO-1996034867-A1 | PYRIDO[2,3-d]PYRIMIDINES FOR INHIBITING PROTEIN TYROSINE KINASE MEDIATED CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1996-11-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080220497-A1 | Modulation of protein functionalities | C1QBP, SERPINA6, CD2BP2 | FGFR1 4698/4885SRC 2604/4885PDGFRB 3462/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | FGFR1 118/4885SRC 9/4885PDGFRB 16/4885 |
| US-20250387643-A1 | METHODS AND APPARATUS FOR APPLYING TUMOR TREATING FIELDS COMBINED WITH PERSONALIZED ULTRA-FRACTIONATED STEREOTACTIC ADAPTIVE RADIOTHERAPY | IFNAR1, IFNG, PDCD1 | FGFR1 1135/4885SRC 1885/4885PDGFRB 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.